浙江临床医学
浙江臨床醫學
절강림상의학
ZHEJIANG CLINICAL MEDICAL JOURNAL
2013年
8期
1134-1136
,共3页
子宫颈癌%MAGE-A%NY-ESO-1%预后
子宮頸癌%MAGE-A%NY-ESO-1%預後
자궁경암%MAGE-A%NY-ESO-1%예후
Cervical cancer%MAGE-A%NY-ESO-1%Prognosis
目的探讨子宫颈癌肿瘤组织中MAGE-A、NY-ESO-1的表达及与临床病理特征、预后关系。方法82例子宫颈癌患者分为两组。A组34例，FIGOⅠa1-Ⅰb1，接受根治性子宫切除术；B组48例，FIGOⅠb2-Ⅳa，接受新辅助化疗方案后行根治性子宫切除术。免疫组化法检测82例患者肿瘤组织中MAGE-A、NY-ESO-1的表达，并与患者临床病理特征及生存时间分析比较。结果 A组MAGE-A、NY-ESO-1阳性率分别为44.1%（15/34）和58.8%（20/34）。B组接受新辅助化疗前MAGE-A、NY-ESO-1的阳性率分别为56.3%（27/48）和54.2%（26/48），新辅助化疗后MAGE-A及NY-ESO-1的阳性率分别为53.5%（23/43）和55.8%（24/43）。A组≥2cm肿瘤MAGE-A、NY-ESO-1的阳性率高于<2cm的肿瘤（P<0.05）。不同N分期MAGE-A表达的阳性率差异也有统计学意义（P<0.05）。MAGE-A阳性患者生存时间低于MAGE-A阴性者（P<0.05）。结论 MAGE-A及NY-ESO-1在子宫颈癌中高表达，并且化疗药物对MAGE-A及NY-ESO-1的表达无影响。MAGE-A与肿瘤直径及淋巴结转移相关，可作为子宫颈癌患者的负性预后因子。
目的探討子宮頸癌腫瘤組織中MAGE-A、NY-ESO-1的錶達及與臨床病理特徵、預後關繫。方法82例子宮頸癌患者分為兩組。A組34例，FIGOⅠa1-Ⅰb1，接受根治性子宮切除術；B組48例，FIGOⅠb2-Ⅳa，接受新輔助化療方案後行根治性子宮切除術。免疫組化法檢測82例患者腫瘤組織中MAGE-A、NY-ESO-1的錶達，併與患者臨床病理特徵及生存時間分析比較。結果 A組MAGE-A、NY-ESO-1暘性率分彆為44.1%（15/34）和58.8%（20/34）。B組接受新輔助化療前MAGE-A、NY-ESO-1的暘性率分彆為56.3%（27/48）和54.2%（26/48），新輔助化療後MAGE-A及NY-ESO-1的暘性率分彆為53.5%（23/43）和55.8%（24/43）。A組≥2cm腫瘤MAGE-A、NY-ESO-1的暘性率高于<2cm的腫瘤（P<0.05）。不同N分期MAGE-A錶達的暘性率差異也有統計學意義（P<0.05）。MAGE-A暘性患者生存時間低于MAGE-A陰性者（P<0.05）。結論 MAGE-A及NY-ESO-1在子宮頸癌中高錶達，併且化療藥物對MAGE-A及NY-ESO-1的錶達無影響。MAGE-A與腫瘤直徑及淋巴結轉移相關，可作為子宮頸癌患者的負性預後因子。
목적탐토자궁경암종류조직중MAGE-A、NY-ESO-1적표체급여림상병리특정、예후관계。방법82례자궁경암환자분위량조。A조34례，FIGOⅠa1-Ⅰb1，접수근치성자궁절제술；B조48례，FIGOⅠb2-Ⅳa，접수신보조화료방안후행근치성자궁절제술。면역조화법검측82례환자종류조직중MAGE-A、NY-ESO-1적표체，병여환자림상병리특정급생존시간분석비교。결과 A조MAGE-A、NY-ESO-1양성솔분별위44.1%（15/34）화58.8%（20/34）。B조접수신보조화료전MAGE-A、NY-ESO-1적양성솔분별위56.3%（27/48）화54.2%（26/48），신보조화료후MAGE-A급NY-ESO-1적양성솔분별위53.5%（23/43）화55.8%（24/43）。A조≥2cm종류MAGE-A、NY-ESO-1적양성솔고우<2cm적종류（P<0.05）。불동N분기MAGE-A표체적양성솔차이야유통계학의의（P<0.05）。MAGE-A양성환자생존시간저우MAGE-A음성자（P<0.05）。결론 MAGE-A급NY-ESO-1재자궁경암중고표체，병차화료약물대MAGE-A급NY-ESO-1적표체무영향。MAGE-A여종류직경급림파결전이상관，가작위자궁경암환자적부성예후인자。
Objective To explore the relationship between the expression of MAGE-A,NY-ESO-1 and the clinical pathologic features and prognosis of cervical cancer and to observe the influence of neoadjuvant chemotherapy on the expression of MAGE-A and NY-ESO-1. Methods 82 cases were divided into two groups. Group A,34 patients of FIGO Ⅰa1-Ⅰb1, who received hysterectomy. Group B,48 patients of FIGO Ⅰb2-Ⅳa,who received neoadjuvant chemotherapy followed by hysterectomy. Immunohistochemistry was used to detect the expressions of MAGE-A,NY-ESO-1 in 82 cases of cervical cancer. Analysis the relationship between the expression of MAGE-A,NY-ESO-1 and pathological properties or prognosis. Results In group A,the positive expression reates of MAGE-A and NY-ESO-1 were 44.1% and 58.8%. In group B,the positive expression reates of MAGE-A and NY-ESO-1 were 56.3% and 54.2% before neoadjuvant chemotherapy. After neoadjuvant chemotherapy, the positive expression reates of MAGE-A and NY-ESO-1 were 53.5% and 55.8%. The positive expression reates of MAGE-A and NY-ESO-1 of tumor diameter ≥2cm were higher than <2cm in group A. The expression of MAGE-A was related with N stage. The survival time of patient with MAGE-A positive was lower than negative(P<0.05). Conclusion MAGE-A and NY-ESO-1 frequently express in cervical cancer. Drugs of chemotherapy were not influence the expression of MAGE-A and NY-ESO-1. MAGE-A is related with tumor diameter and lymph node metastases.
